Dr. Arnold has received consulting fees, speaking fees, and/or honoraria from Cypress Bioscience, Wyeth, Boehringer Ingelheim, Allergan, Takeda, UCB, Theravance, AstraZeneca, and Sanofi-Aventis (less than $10,000 each) and from Eli Lilly, Pfizer, and Forest Laboratories (more than $10,000 each) and has received research support from Eli Lilly, Cypress Bioscience, Wyeth, Boehringer Ingelheim, Allergan, Forest Laboratories, and Pfizer.
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Fibromyalgia
You have full text access to this OnlineOpen article
Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, double-blind, placebo-controlled trial†
Article first published online: 21 MAY 2010
DOI: 10.1002/art.27559
Copyright © 2010 by the American College of Rheumatology
Additional Information
How to Cite
Arnold, L. M., Gendreau, R. M., Palmer, R. H., Gendreau, J. F. and Wang, Y. (2010), Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 62: 2745–2756. doi: 10.1002/art.27559
- †
Clinical Trials.gov identifier: NCT00314249.
- ‡
Dr. Arnold has received consulting fees, speaking fees, and/or honoraria from Cypress Bioscience, Wyeth, Boehringer Ingelheim, Allergan, Takeda, UCB, Theravance, AstraZeneca, and Sanofi-Aventis (less than $10,000 each) and from Eli Lilly, Pfizer, and Forest Laboratories (more than $10,000 each) and has received research support from Eli Lilly, Cypress Bioscience, Wyeth, Boehringer Ingelheim, Allergan, Forest Laboratories, and Pfizer.
- §
Drs. R. M. Gendreau and J. F. Gendreau own stock or stock options in Cypress Bioscience.
- ¶
Drs. Palmer and Wang own stock or stock options in Forest Laboratories.
Publication History
- Issue published online: 31 AUG 2010
- Article first published online: 21 MAY 2010
- Manuscript Accepted: 6 MAY 2010
- Manuscript Received: 25 NOV 2009
Funded by
- Forest Laboratories, Inc.
REFERENCES
- 1, , , , . The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19–28.
- 2, , , , , , et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72.
- 3, , , , , , et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008; 73: 114–20.
- 4, . The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008; 62: 115–26.
- 5, , , , , , et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol 2009; 36: 2318–29.
- 6, , , , , , et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial [published erratum appears in J Rheumatol 2009;36:661]. J Rheumatol 2009; 36: 398–409.
- 7, , , , . Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial [published erratum appears in Clin Ther 2009;31:446]. Clin Ther 2008; 30: 1988–2004.
- 8Savella [package insert]: St. Louis (MO): Forest Pharmaceuticals, Inc.; 2009.
- 9, , . Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991; 14: 219–45.
- 10. Descending control of pain. Prog Neurobiol 2002; 66: 355–474.
- 11, . Pharmacotherapy of fibromyalgia. Rheum Dis Clin North Am 2009; 35: 359–72.
- 12, , . The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991; 18: 728–33.
- 13, , , , . An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71.
- 14, , , , , , et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 Suppl 20: 22–33.
- 15, . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83.
- 16, , , . The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 315–25.
- 17, , , . An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893–7.
- 18, , , , . Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol 1994; 16: 93–104.
- 19
- 20, , , . A closer look at the baseline-observation-carried-forward (BOCF). Patient Prefer Adherence 2010; 4: 11–6.
- 21. Handling missing data in clinical trials: an overview. Drug Inf J 2000; 34: 525–33.
- 22, , . The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. Int J Clin Pract 2008; 62: 1147–58.
- 23, , . Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997; 16: 2349–80.
- 24, , , , . Real longitudinal data analysis for real people: building a good enough mixed model. Stat Med 2010; 29: 504–20.
- 25, . Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. J Stat Plan Inference 2001; 99: 25–40.
- 26, , , , . Composite responder endpoints for fibromyalgia trials: experience with milnacipran [abstract]. Arthritis Rheum 2007; 56 Suppl: S603.
- 27, , , , , . The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009; 11: R120.
- 28. Duloxetine and pregabalin: safe and effective for the long-term treatment of fibromyalgia? Nat Clin Pract Neurol 2008; 4: 594–5.
- 29, . A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol 2009; 5: 191–9.
- 30. Pharmacotherapy for patients with fibromyalgia. J Clin Psychiatry 2008; 69 Suppl 2: 25–9.
- 31, , , , , . A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. Clin Rheumatol 2008; 27: 1543–7.
- 32, , . Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin Rheumatol 2009; 28: 475–8.
- 33World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Technical Report Series 894. Geneva: World Health Organization; 2000. URL: http://whqlibdoc.who.int/trs/WHO_TRS_894.pdf.
- 34, , , , , . Durability of therapeutic response to milnacipran for fibromyalgia: results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010; 11: 180–94.